TD Asset Management Inc Buys 41,826 Shares of QuidelOrtho Corporation $QDEL

Posted by Brian Himes on Jun 9th, 2026

TD Asset Management Inc increased its stake in shares of QuidelOrtho Corporation (NASDAQ:QDEL – Free Report) by 8.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 524,592 shares of the company’s stock after purchasing an additional 41,826 shares during the quarter. TD Asset Management Inc’s holdings in QuidelOrtho were worth $14,982,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of QDEL. Global Retirement Partners LLC grew its stake in shares of QuidelOrtho by 3,691.7% during the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after purchasing an additional 886 shares during the last quarter. Camelot Portfolios LLC bought a new stake in shares of QuidelOrtho during the fourth quarter valued at approximately $29,000. Hantz Financial Services Inc. grew its stake in shares of QuidelOrtho by 50.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after purchasing an additional 362 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of QuidelOrtho by 322.2% during the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after purchasing an additional 1,015 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of QuidelOrtho during the third quarter valued at approximately $63,000. 99.00% of the stock is owned by institutional investors.

QuidelOrtho Price Performance

Shares of QDEL stock opened at $14.47 on Tuesday. QuidelOrtho Corporation has a 52-week low of $9.92 and a 52-week high of $35.58. The stock has a market cap of $986.72 million, a PE ratio of -0.81 and a beta of 0.77. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. The firm’s 50 day moving average price is $13.17 and its two-hundred day moving average price is $21.51.

QuidelOrtho (NASDAQ:QDEL – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The business had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. During the same period in the previous year, the business posted $0.74 earnings per share. QuidelOrtho’s revenue was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. As a group, analysts forecast that QuidelOrtho Corporation will post 1.83 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Zacks Research cut shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. UBS Group reaffirmed a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a research note on Thursday, May 7th. Jefferies Financial Group cut shares of QuidelOrtho from a “buy” rating to a “hold” rating and reduced their price objective for the company from $35.00 to $12.50 in a research note on Thursday, May 7th. Finally, Citigroup reduced their price objective on shares of QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Three research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $14.88.

Check Out Our Latest Research Report on QuidelOrtho

QuidelOrtho Company Profile

(Free Report)

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.